Key result
Aliskiren prevents hyperhomocysteinemia-induced myocardial fibrosis and diastolic dysfunction in mice.
Why the study?
Does aliskiren prevent myocardial fibrosis in preclinical models of hyperhomocysteinemia?
Population
Adult mice fed hyperhomocysteinemia-inducing diet and adult rat cardiac fibroblasts
Comparison
Aliskiren vs Vehicle
Design
Preclinical
Follow-up
12 weeks (in vivo)
Authors
Loading...
Hypothesis-generating for aliskiren in hyperhomocysteinemia-related diastolic dysfunction; human trials needed before clinical consideration.
Does aliskiren prevent myocardial fibrosis in preclinical models of hyperhomocysteinemia?
p-value: p=<0.05
Aliskiren demonstrates direct anti-fibrotic effects on myocardial matrix turnover and improves diastolic function in preclinical models of myocardial fibrosis.
Zhi et al. (2013) studied Myocardial fibrosis. Aliskiren vs. Vehicle was evaluated on Myocardial fibrosis and diastolic function (p=<0.05). Aliskiren prevented hyperhomocysteinemia-induced myocardial collagen deposition and diastolic dysfunction in mice, demonstrating direct anti-fibrotic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: